Caribou Biosciences Analyst Ratings
Caribou Biosciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | — | Cantor Fitzgerald | Initiates Coverage On | → Neutral | |
| 07/26/2023 | 394.62% | HC Wainwright & Co. | $25 → $23 | Maintains | Buy |
| 07/14/2023 | 394.62% | Truist Securities | $23 → $23 | Reiterates | Buy → Buy |
| 07/11/2023 | 394.62% | Truist Securities | → $23 | Initiates Coverage On | → Buy |
| 05/10/2023 | 437.63% | HC Wainwright & Co. | $26 → $25 | Maintains | Buy |
| 03/14/2023 | 459.14% | HC Wainwright & Co. | $27 → $26 | Maintains | Buy |
| 03/10/2023 | 308.6% | RBC Capital | → $19 | Reiterates | → Outperform |
| 03/10/2023 | 588.17% | Oppenheimer | $36 → $32 | Maintains | Outperform |
| 08/29/2022 | 717.2% | Citigroup | $39 → $38 | Maintains | Buy |
| 08/18/2022 | 480.65% | HC Wainwright & Co. | $28 → $27 | Maintains | Buy |
| 08/10/2022 | 308.6% | RBC Capital | $22 → $19 | Maintains | Outperform |
| 05/13/2022 | 738.71% | Citigroup | $29 → $39 | Maintains | Buy |
| 05/12/2022 | 631.18% | SVB Leerink | $30 → $34 | Maintains | Outperform |
| 05/10/2022 | 545.16% | SVB Leerink | $29 → $30 | Maintains | Outperform |
| 03/22/2022 | 523.66% | SVB Leerink | $32 → $29 | Maintains | Outperform |
| 02/18/2022 | 373.12% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 02/14/2022 | 308.6% | Brookline Capital | → $19 | Initiates Coverage On | → Buy |
| 12/01/2021 | 674.19% | Oppenheimer | → $36 | Initiates Coverage On | → Outperform |
| 11/30/2021 | 502.15% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
| 11/15/2021 | 480.65% | Citigroup | → $27 | Upgrades | Neutral → Buy |
| 08/17/2021 | 480.65% | Citigroup | → $27 | Initiates Coverage On | → Neutral |
| 08/17/2021 | 545.16% | B of A Securities | → $30 | Initiates Coverage On | → Buy |
| 08/17/2021 | 588.17% | SVB Leerink | → $32 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/08/2023 | — | 坎托·菲茨杰拉德 | 启动覆盖范围开启 | → 中立 | |
| 07/26/2023 | 394.62% | HC Wainwright & Co. | 25 美元 → 23 美元 | 维护 | 买 |
| 07/14/2023 | 394.62% | 信实证券 | 23 美元 → 23 美元 | 重申 | 购买 → 购买 |
| 07/11/2023 | 394.62% | 信实证券 | → 23 美元 | 启动覆盖范围开启 | → 购买 |
| 05/10/2023 | 437.63% | HC Wainwright & Co. | 26 美元 → 25 美元 | 维护 | 买 |
| 03/14/2023 | 459.14% | HC Wainwright & Co. | 27 美元 → 26 美元 | 维护 | 买 |
| 03/10/2023 | 308.6% | 加拿大皇家银行资本 | → 19 美元 | 重申 | → 跑赢大盘 |
| 03/10/2023 | 588.17% | 奥本海默 | 36 美元 → 32 美元 | 维护 | 跑赢大盘 |
| 08/29/2022 | 717.2% | 花旗集团 | 39 美元 → 38 美元 | 维护 | 买 |
| 08/18/2022 | 480.65% | HC Wainwright & Co. | 28 美元 → 27 美元 | 维护 | 买 |
| 08/10/2022 | 308.6% | 加拿大皇家银行资本 | 22 美元 → 19 美元 | 维护 | 跑赢大盘 |
| 05/13/2022 | 738.71% | 花旗集团 | 29 美元 → 39 美元 | 维护 | 买 |
| 05/12/2022 | 631.18% | SVB Leerink | 30 美元 → 34 美元 | 维护 | 跑赢大盘 |
| 05/10/2022 | 545.16% | SVB Leerink | 29 美元 → 30 美元 | 维护 | 跑赢大盘 |
| 03/22/2022 | 523.66% | SVB Leerink | 32 美元 → 29 美元 | 维护 | 跑赢大盘 |
| 2022 年 2 月 18 日 | 373.12% | 加拿大皇家银行资本 | → 22 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 02/14/2022 | 308.6% | 布鲁克林资本 | → 19 美元 | 启动覆盖范围开启 | → 购买 |
| 12/01/2021 | 674.19% | 奥本海默 | → 36 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 11 月 30 日 | 502.15% | HC Wainwright & Co. | → 28 美元 | 启动覆盖范围开启 | → 购买 |
| 11/15/2021 | 480.65% | 花旗集团 | → 27 美元 | 升级 | 中性 → 买入 |
| 2021 年 8 月 17 日 | 480.65% | 花旗集团 | → 27 美元 | 启动覆盖范围开启 | → 中立 |
| 2021 年 8 月 17 日 | 545.16% | B of A 类证券 | → 30 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 8 月 17 日 | 588.17% | SVB Leerink | → 32 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for Caribou Biosciences (CRBU)?
Caribou Biosciences (CRBU) 的目标价格是多少？
The latest price target for Caribou Biosciences (NASDAQ: CRBU) was reported by Cantor Fitzgerald on November 8, 2023. The analyst firm set a price target for $0.00 expecting CRBU to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年11月8日公布了Caribou Biosciences（纳斯达克股票代码：CRBU）的最新目标股价。该分析公司将目标股价定为0.00美元，预计CRBU将在12个月内降至12个月内（可能下跌-100.00％）。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Caribou Biosciences (CRBU)?
Caribou Biosciences（CRBU）的最新分析师评级是多少？
The latest analyst rating for Caribou Biosciences (NASDAQ: CRBU) was provided by Cantor Fitzgerald, and Caribou Biosciences initiated their neutral rating.
Caribou Biosciences（纳斯达克股票代码：CRBU）的最新分析师评级由坎托·菲茨杰拉德提供，Caribou Biosciences启动了中性评级。
When is the next analyst rating going to be posted or updated for Caribou Biosciences (CRBU)?
Caribou Biosciences（CRBU）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Caribou Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Caribou Biosciences was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Caribou Biosciences的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Caribou Biosciences的最新评级是在2023年11月8日公布的，因此您应该预计下一个评级将在2024年11月8日左右公布。
Is the Analyst Rating Caribou Biosciences (CRBU) correct?
分析师对 Caribou Biosciences (CRBU) 的评级正确吗？
While ratings are subjective and will change, the latest Caribou Biosciences (CRBU) rating was a initiated with a price target of $0.00 to $0.00. The current price Caribou Biosciences (CRBU) is trading at is $4.65, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Caribou Biosciences（CRBU）评级最初是以0.00美元至0.00美元的目标股价为起步的。Caribou Biosciences（CRBU）目前的交易价格为4.65美元，超出了分析师的预期区间。